VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 27, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that it has begun dosing its first patient for a Phase Ib human clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company’s second product AL-208 as a treatment for neurodegenerative indications where multiple doses are required.
